0001209191-22-059882.txt : 20221205 0001209191-22-059882.hdr.sgml : 20221205 20221205195038 ACCESSION NUMBER: 0001209191-22-059882 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221205 DATE AS OF CHANGE: 20221205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Olagunju Peter CENTRAL INDEX KEY: 0001875057 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 221446390 MAIL ADDRESS: STREET 1: TCR2 THERAPEUTICS INC. STREET 2: 100 BINNEY STREET, SUITE 710 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-01 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001875057 Olagunju Peter 100 BINNEY STREET BOSTON MA 02142 0 1 0 0 Chief Technical Officer Common Stock 2192 D Common Stock 2022-12-01 4 M 0 33409 A 35601 D Common Stock 2022-12-02 4 S 0 1273 1.387 D 34328 D Restricted Stock Unit 2022-12-01 4 M 0 33409 0.00 A Common Stock 33409 62047 D Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program. Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. 35% of these restricted stock units vested on December 1, 2022, 25% will vest on each of December 1, 2023 and December 1, 2024, and the remaining 15% will vest on December 1, 2025. Margaret Siegel as Attorney-In-Fact 2022-12-05